In summary, combining Roscovitine with anti-PD-1 offers a promising strategy to enhance ICB by modulating immune cell populations, reducing MDSC-driven suppression, and decreasing PD-L1 expression in the tumor microenvironment. Here, CD274 is linked to neoplasm.